Vascular lesions within and adjacent to vessels in the body can be associated with an increased risk for major adverse events, such as myocardial infarction, embolism, deep vein thrombosis, stroke, and the like. Severe vascular lesions can be difficult to treat and achieve patency for a physician in a clinical setting.
Vascular lesions may be treated using interventions such as drug therapy, balloon angioplasty, atherectomy, stent placement, vascular graft bypass, to name a few. Such interventions may not always be ideal or may require subsequent treatment to address the lesion.
Using optical fiber delivery of laser pulses to generate high-pressure impulses on the lesions is one way to attempt to treat the lesions. Creation of a plasma via optical breakdown of an aqueous solution typically requires a significant amount of energy in a short amount of time upon which it is converted into a therapeutic bubble and/or a therapeutic pressure wave. With sufficiently high energy and short pulse durations, there is potential to damage a proximal end and/or a distal end of the optical fiber used to deliver light energy to generate the plasma. This damage to the proximal end of the optical fiber usually manifests as surface damage. The amount of energy that can be transmitted through the fiber is limited by the peak intensity of the pulse on the proximal surface of the fiber. Additionally, for pulses with an approximately Gaussian temporal shape, the peak pressure generated by the optical pulse is approximately proportional to the peak intensity of the pulse.
Further, creation of the plasma near the distal end of the optical fiber as in the case of aqueous optical breakdown as one method for an intravascular lithoplasty catheter has the potential for self-damage due to its proximity to the plasma creation and/or the pressure wave, high plasma temperatures, and waterjet from collapse of the bubble, as non-exclusive examples.
The present invention is directed toward a catheter system for treating a treatment site within or adjacent to a vessel wall. In various embodiments, the catheter system includes an inflatable balloon, an optical fiber and a laser. The optical fiber can have a distal end that is positioned within the inflatable balloon. The optical fiber can be configured to receive an energy pulse so that the optical fiber emits light energy in a direction away from the optical fiber to generate a plasma pulse within the inflatable balloon. The laser can include (i) a seed source that is configured to emit a seed pulse, and (ii) an amplifier that is configured to increase energy of the seed pulse so that the laser generates the energy pulse that is received by the optical fiber. In certain embodiments, the energy pulse can have a waveform with a duration T, a minimum power P0, a peak power PP, and a time from P0 to PP equal to TP, wherein TP is not greater than 40% of T.
In some embodiments, TP is not greater than 10% of T.
In various embodiments, T can be within the range of greater than 50 ns and less than 3 μs.
In certain embodiments, T can be within the range of greater than 300 ns and less than 800 ns.
In some embodiments, TP can be within the range of greater than 2.5 ns and less than 1 μs.
In various embodiments, TP can be within the range of greater than 15 ns and less than 300 ns.
In some embodiments, PP can be within the range of greater than 50 kW and less than 1000 kW.
In certain embodiments, PP is within the range of greater than 100 kW and less than 500 kW.
In various embodiments, a ratio in kW to ns of PP to TP can be greater than 1:5.
In some embodiments, a ratio in kW to ns of PP to TP can be greater than 5:1.
In certain embodiments, the waveform can approximate a square wave.
In various embodiments, the waveform can approximate a triangular wave.
In some embodiments, the seed pulse can at least partially increase in amplitude over time.
The present invention is also directed toward a method for treating a treatment site within or adjacent to a vessel wall. In various embodiments, the method can include one or more of the steps of positioning a distal end of an optical fiber within an inflatable balloon; delivering an energy pulse to the optical fiber with a laser that includes (i) a seed source that is configured to emit a seed pulse, and (ii) an amplifier that is configured to increase energy of the seed pulse, the energy pulse having a waveform with a duration T, a minimum power P0, a peak power PP, and a time from P0 to PP equal to TP, wherein TP is not greater than 40% of T; and the optical fiber emitting light energy in a direction away from the optical fiber upon receiving the energy pulse to generate a plasma pulse within the inflatable balloon.
The present invention is also directed toward a catheter system for treating a treatment site within or adjacent to a vessel wall. In various embodiments, the catheter system can include an inflatable balloon, an optical fiber and a laser. In some embodiments, the optical fiber can have a distal end that is positioned within the inflatable balloon. The optical fiber can be configured to receive an energy pulse so that the optical fiber emits light energy in a direction away from the optical fiber to generate a plasma pulse within the inflatable balloon. The laser can include (i) a seed source that is configured to emit a seed pulse that at least partially increases in amplitude over time, and (ii) an amplifier that is configured to increase energy of the seed pulse so that the laser generates the energy pulse that is received by the optical fiber. In certain embodiments, the energy pulse can have a waveform that approximates one of (i) a square wave, and (ii) a triangular wave. The waveform can have a duration T, a minimum power P0, a peak power PP, and a time from P0 to PP equal to TP. In some embodiments, TP is not greater than 40% of T, T is within the range of greater than 50 ns and less than 3 μs, TP is within the range of greater than 2.5 ns and less than 1 μs, PP is within the range of greater than 50 kW and less than 1000 kW, and a ratio in kW to ns of PP to TP is greater than 1:1.
This summary is an overview of some of the teachings of the present application and is not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details are found in the detailed description and appended claims. Other aspects will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof, each of which is not to be taken in a limiting sense. The scope herein is defined by the appended claims and their legal equivalents.
The novel features of this invention, as well as the invention itself, both as to its structure and its operation, will be best understood from the accompanying drawings, taken in conjunction with the accompanying description, in which similar reference characters refer to similar parts, and in which:
While embodiments are susceptible to various modifications and alternative forms, specifics thereof have been shown by way of example and drawings, and will be described in detail. It should be understood, however, that the scope herein is not limited to the particular aspects described. On the contrary, the intention is to cover modifications, equivalents, and alternatives falling within the spirit and scope herein.
Treatment of vascular lesions can reduce major adverse events or death in affected subjects. A major adverse event is one that can occur anywhere within the body due to the presence of a vascular lesion. Major adverse events can include, but are not limited to major adverse cardiac events, major adverse events in the peripheral or central vasculature, major adverse events in the brain, major adverse events in the musculature, or major adverse events in any of the internal organs.
As used herein, the treatment site can include a vascular lesion such as a calcified vascular lesion or a fibrous vascular lesion (hereinafter sometimes referred to simply as a “lesion”), typically found in a blood vessel and/or a heart valve. Plasma formation can initiate a pressure wave and can initiate the rapid formation of one or more bubbles that can rapidly expand to a maximum size and then dissipate through a cavitation event that can also launch a pressure wave upon collapse. The rapid expansion of the plasma-induced bubbles can generate one or more pressure waves within a balloon fluid and thereby impart pressure waves upon the treatment site. The pressure waves can transfer mechanical energy through an incompressible balloon fluid to a treatment site to impart a fracture force on the lesion. Without wishing to be bound by any particular theory, it is believed that the rapid change in balloon fluid momentum upon a balloon wall of the inflatable balloon that is in contact with or positioned near the lesion is transferred to the lesion to induce fractures in the lesion.
Those of ordinary skill in the art will realize that the following detailed description of the present invention is illustrative only and is not intended to be in any way limiting. Other embodiments of the present invention will readily suggest themselves to such skilled persons having the benefit of this disclosure. Additionally, other methods of delivering energy to the lesion can be utilized, including, but not limited to, electric current induced plasma generation. Reference will now be made in detail to implementations of the present invention as illustrated in the accompanying drawings.
In the interest of clarity, not all of the routine features of the implementations described herein are shown and described. It will, of course, be appreciated that in the development of any such actual implementation, numerous implementation-specific decisions must be made in order to achieve the developer's specific goals, such as compliance with application-related and business-related constraints, and that these specific goals will vary from one implementation to another and from one developer to another. Moreover, it is appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking of engineering for those of ordinary skill in the art having the benefit of this disclosure.
As used herein, the terms “intravascular lesion”, “vascular lesion” and “treatment site” are used interchangeably unless otherwise noted, and can include lesions located at or near blood vessels or heart valves.
It is appreciated that the catheter systems herein can include many different forms and/or configurations other than those specifically shown and/or described herein. Referring now to
The catheter 102 includes an inflatable balloon 104 (sometimes referred to herein as “balloon”). The catheter 102 is configured to move to a treatment site 106 within or adjacent to a blood vessel 108 or a heart valve. The treatment site 106 can include a vascular lesion such as a calcified vascular lesion, for example. Additionally, or in the alternative, the treatment site 106 can include a vascular lesion such as a fibrous vascular lesion.
The catheter 102 can include the balloon 104, a catheter shaft 110 and a guidewire 112. The balloon can be coupled to the catheter shaft 110. The balloon can include a balloon proximal end 104P and a balloon distal end 104D. The catheter shaft 110 can extend between a shaft proximal end 114 and a shaft distal end 116. The catheter shaft 110 can include a guidewire lumen 118 which is configured to move over the guidewire 112. The catheter shaft 110 can also include an inflation lumen (not shown). In some embodiments, the catheter 102 can have a distal end opening 120 and can accommodate and be moved over and/or along the guidewire 112 so that the balloon 104 is positioned at or near the treatment site 106.
The balloon 104 can include a balloon wall 130. The balloon 104 can expand from a collapsed configuration suitable for advancing at least a portion of the catheter shaft 102 through a patient's vasculature to an expanded configuration suitable for anchoring the catheter 102 into position relative to the treatment site 106.
The catheter shaft 110 of the catheter 102 can encircle one or more optical fibers 122 (only one optical fiber 122 is illustrated in
The optical fiber 122 has a fiber proximal end 122P that is positioned at or adjacent to the laser 124. The optical fiber 122 extends between the laser 124 and the balloon 104. The optical fiber 122 is in optical communication with the laser 124.
The controller 123 can control the laser 124 so that the laser 124 can generate one or more energy pulses 431 (illustrated in
The laser 124 of the catheter system 100 can be configured to provide one or more sub-millisecond energy pulses 431 that are sent to and received by the optical fiber 122. The optical fiber 122 acts as a conduit for light energy that is generated by the energy pulse(s) 431. In certain embodiments, the laser 124 can include one or more seed sources 126 and one or more amplifiers 128. Each amplifier 128 can be in optical communication with at least one of the seed sources 126. The seed source(s) 126 can each emit a relatively low-power seed pulse that is received and amplified by the amplifier 128. The amplifier 128 can increase the power of the seed pulse to generate the energy pulse 431. In one embodiment, the laser 124 can include one seed source 126 and one amplifier 128. Alternatively, the laser 124 can include a plurality of seed sources 126 and one amplifier 128. Still alternatively, the laser 124 can include a plurality of seed sources 126 and a plurality of amplifiers 128.
The light energy that is generated by the energy pulse(s) 431 is delivered by the optical fiber 122 to a location within the balloon 104. The light energy induces plasma formation in the form of a plasma pulse 134 that occurs in the balloon fluid 132 within the balloon 104. The plasma pulse 134 causes rapid bubble formation, and imparts pressure waves upon the treatment site 106. Exemplary plasma pulses 134 are shown in
In various embodiments, the sub-millisecond pulses of light can be delivered to near the treatment site 106 at a frequency of from at least approximately 1 hertz (Hz) up to approximately 5000 Hz. In some embodiments, the sub-millisecond pulses of light can be delivered to near the treatment site 106 at a frequency from at least 30 Hz to 1000 Hz. In other embodiments, the sub-millisecond pulses of light can be delivered to near the treatment site 106 at a frequency from at least 10 Hz to 100 Hz. In yet other embodiments, the sub-millisecond pulses of light can be delivered to near the treatment site 106 at a frequency from at least 1 Hz to 30 Hz.
It is appreciated that the catheter system 100 herein can include any number of optical fibers 122 in optical communication with the laser 124 at the proximal portion 114, and with the balloon fluid 132 within the balloon 104 at the distal portion 116. For example, in some embodiments, the catheter system 100 herein can include 1-30 optical fibers 122. In some embodiments, the catheter system 100 herein can include greater than 30 optical fibers.
The manifold 136 can be positioned at or near the shaft proximal end 114. The manifold 136 can include one or more proximal end openings that can receive the one or more optical fibers, such as optical fiber 122, the guidewire 112, and/or an inflation conduit 140. The catheter system 100 can also include the fluid pump 138 that is configured to inflate the balloon 104 with the balloon fluid 132 and/or deflate the balloon 104 as needed.
As with all embodiments illustrated and described herein, various structures may be omitted from the figures for clarity and ease of understanding. Further, the figures may include certain structures that can be omitted without deviating from the intent and scope of the invention.
In this embodiment, using the first square wave 231F with the same peak amplitude of the Gaussian energy pulse 231G and a pulse width equal to the FWHM of the Gaussian energy pulse 231G puts at least approximately 23% more power into the optical fiber 122. Since plasma initiation typically occurs at 20% or less of this peak value, and the second square energy pulse 231S can be scaled to equal time above threshold, at least 54% more energy can be put through the optical fiber 122. In an alternative embodiment, similar or equivalent energy can be put through the optical fiber 122 in the same time at a lower peak power, allowing operation further below the absolute damage threshold of the optical fiber 122.
The optically generated plasma events that produce the desired pressure waves generally have an initiation threshold below (<20%) the damage threshold of the optical fiber 122. A faster rise time on the optical pulse (approaching a square wave), can allow more energy to be pumped into the plasma and bubble while both have minimal spatial extent. This can more efficiently pump energy into the pressure pulse and can thereby allow the generation of larger pressure gradients while using a lower optical pulse energy. Consequently, sufficiently energetic pressure waves can potentially be created to fracture calcified lesions while remaining well below the damage threshold of the optical fiber 122.
In one embodiment, a MOPA (Master Oscillator—Power Amplifier) can be used to produce the required pulse energy, beam quality, and pulse length. With this design, a well-controlled seed source 126, such as a low-power master oscillator, can seed the amplifier 128 (illustrated in
The shape of the seed pulse 342 illustrated in the embodiment shown in
In the embodiment illustrated in
In this embodiment, TP of the energy pulse 431 can have a duration within the range of greater than 2.5 ns and less than 1 μs. In non-exclusive alternative embodiments, TP can have a duration within the range of greater than 5 ns and less than 800 ns, within the range of greater than 10 ns and less than 400 ns, within the range of greater than 15 ns and less than 300 ns, or within the range of greater than 30 ns and less than 100 ns. Still alternatively, TP can have a duration within or outside of the foregoing ranges.
In the embodiment illustrated in
In this embodiment, the energy pulse 431 can have a ratio of PP to TP (in kW to ns) that is greater than 1:5. In non-exclusive alternative embodiments, the energy pulse 431 can have a ratio of PP to TP (in kW to ns) that is greater than 1:3, 1:1, 2:1, 3:1, 5:1, 10:1, or 20:1.
In the embodiment illustrated in
In this embodiment, TP of the energy pulse 531 can have a duration within the range of greater than 2.5 ns and less than 1 μs. In non-exclusive alternative embodiments, TP can have a duration within the range of greater than 5 ns and less than 800 ns, within the range of greater than 10 ns and less than 400 ns, within the range of greater than 15 ns and less than 300 ns, or within the range of greater than 30 ns and less than 100 ns. Still alternatively, TP can have a duration within or outside of the foregoing ranges.
In the embodiment illustrated in
In this embodiment, the energy pulse 531 can have a ratio of PP to TP (in kW to ns) that is greater than 1:5. In non-exclusive alternative embodiments, the energy pulse 531 can have a ratio of PP to TP (in kW to ns) that is greater than 1:3, 1:1, 2:1, 3:1, 5:1, 10:1, or 20:1.
In the embodiment illustrated in
In this embodiment, TP of the energy pulse 631 can have a duration within the range of greater than 2.5 ns and less than 1 μs. In non-exclusive alternative embodiments, TP can have a duration within the range of greater than 5 ns and less than 800 ns, within the range of greater than 10 ns and less than 400 ns, within the range of greater than 15 ns and less than 300 ns, or within the range of greater than 30 ns and less than 100 ns. Still alternatively, TP can have a duration within or outside of the foregoing ranges.
In the embodiment illustrated in
In this embodiment, the energy pulse 631 can have a ratio of PP to TP (in kW to ns) that is greater than 1:5. In non-exclusive alternative embodiments, the energy pulse 631 can have a ratio of PP to TP (in kW to ns) that is greater than 1:3, 1:1, 2:1, 3:1, 5:1, 10:1, or 20:1.
It is recognized that any temporal energy pulse shape that features a relatively fast rise time and attempts to decrease the overshot on the leading edge of the energy pulse should allow more efficient plasma generation thorough an optical fiber without damaging the optical fiber. For example, any temporal energy pulse shape which features a faster rise (and fall) than a Gaussian could reap the benefits of this invention.
The present invention is also directed toward methods for treating a treatment site within or adjacent to a vessel wall, with such methods utilizing the devices disclosed herein.
The lasers suitable for use herein can include various types of lasers including lasers and lamps. Suitable lasers can include short pulse lasers on the sub-millisecond timescale. In some embodiments, the laser can include lasers on the nanosecond (ns) timescale. The lasers can also include short pulse lasers on the picosecond (ps), femtosecond (fs), and microsecond (us) timescales. It is appreciated that there are many combinations of laser wavelengths, pulse widths and energy levels that can be employed to achieve plasma in the balloon fluid of the catheters illustrated and/or described herein. In various embodiments, the pulse widths can include those falling within a range including from at least 10 ns to 200 ns. In some embodiments, the pulse widths can include those falling within a range including from at least 20 ns to 100 ns. In other embodiments, the pulse widths can include those falling within a range including from at least 1 ns to 5000 ns.
Exemplary nanosecond lasers can include those within the UV to IR spectrum, spanning wavelengths of about 10 nanometers to 1 millimeter. In some embodiments, the lasers suitable for use in the catheter systems herein can include those capable of producing light at wavelengths of from at least 750 nm to 2000 nm. In some embodiments, the lasers can include those capable of producing light at wavelengths of from at least 700 nm to 3000 nm. In some embodiments, the lasers can include those capable of producing light at wavelengths of from at least 100 nm to 10 micrometers (μm). Nanosecond lasers can include those having repetition rates of up to 200 kHz. In some embodiments, the laser can include a Q-switched thulium:yttrium-aluminum-garnet (Tm:YAG) laser. In some embodiments, the laser can include a neodymium:yttrium-aluminum-garnet (Nd:YAG), holmium:yttrium-aluminum-garnet (Ho:YAG), erbium:yttrium-aluminum-garnet (Er:YAG), excimer laser, helium-neon laser, carbon dioxide laser, as well as doped, pulsed, fiber lasers.
The catheters illustrated and/or described herein can generate pressure waves having maximum pressures in the range of at least 1 megapascal (MPa) to 100 MPa. The maximum pressure generated by a particular catheter will depend on the laser, the absorbing material, the bubble expansion, the propagation medium, the balloon material, and other factors. In some embodiments, the catheters illustrated and/or described herein can generate pressure waves having maximum pressures in the range of at least 2 MPa to 50 MPa. In other embodiments, the catheters illustrated and/or described herein can generate pressure waves having maximum pressures in the range of at least 2 MPa to 30 MPa. In yet other embodiments, the catheters illustrated and/or described herein can generate pressure waves having maximum pressures in the range of at least 15 MPa to 25 MPa. In some embodiments, the catheters illustrated and/or described herein can generate pressure waves having peak pressures of greater than or equal to 1 MPa, 2 MPa, 3 MPa, 4 MPa, 5 MPa, 6 MPa, 7 MPa, 8 MPa, 9 MPa, 10 MPa, 11 MPa, 12 MPa, 13 MPa, 14 MPa, 15 MPa, 16 MPa, 17 MPa, 18 MPa, 19 MPa, 20 MPa, 21 MPa, 22 MPa, 23 MPa, 24 MPa, or 25 MPa, 26 MPa, 27 MPa, 28 MPa, 29 MPa, 30 MPa, 31 MPa, 32 MPa, 33 MPa, 34 MPa, 35 MPa, 36 MPa, 37 MPa, 38 MPa, 39 MPa, 40 MPa, 41 MPa, 42 MPa, 43 MPa, 44 MPa, 45 MPa, 46 MPa, 47 MPa, 48 MPa, 49 MPa, or 50 MPa. It is appreciated that the catheters illustrated and/or described herein can generate pressure waves having operating pressures or maximum pressures that can fall within a range, wherein any of the forgoing numbers can serve as the lower or upper bound of the range, provided that the lower bound of the range is a value less than the upper bound of the range.
Therapeutic treatment can act via a fatigue mechanism or a brute force mechanism. For a fatigue mechanism, operating pressures would be about at least 0.5 MPa to 2 MPa, or about 1 MPa. For a brute force mechanism, operating pressures would be about at least 20 MPa to 30 MPa, or about 25 MPa. Pressures between the extreme ends of these two ranges may act upon a treatment site using a combination of a fatigue mechanism and a brute force mechanism.
The pressure waves described herein can be imparted upon the treatment site from a distance within a range from at least 0.01 millimeters (mm) to 25 mm extending radially from a longitudinal axis of a catheter placed at a treatment site. In some embodiments, the pressure waves can be imparted upon the treatment site from a distance within a range from at least 1 mm to 20 mm extending radially from a longitudinal axis of a catheter placed at a treatment site. In other embodiments, the pressure waves can be imparted upon the treatment site from a distance within a range from at least 0.1 mm to 10 mm extending radially from a longitudinal axis of a catheter placed at a treatment site. In yet other embodiments, the pressure waves can be imparted upon the treatment site from a distance within a range from at least 1.5 mm to 4 mm extending radially from a longitudinal axis of a catheter placed at a treatment site. In some embodiments, the pressure waves can be imparted upon the treatment site from a range of at least 2 MPa to 30 MPa at a distance from 0.1 mm to 10 mm. In some embodiments, the pressure waves can be imparted upon the treatment site from a range of at least 2 MPa to 25 MPa at a distance from 0.1 mm to 10 mm. In some embodiments, the pressure waves can be imparted upon the treatment site from a distance that can be greater than or equal to 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, or 0.9 mm, 1 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, or 10 mm, or can be an amount falling within a range between, or outside the range of any of the foregoing.
By shaping the temporal form of the optical pulse to have a fast rise time and minimal overshoot (ideally approaching a square wave), the efficiency for generating the pressure wave can be improved, and the amount of energy that can be delivered in a given time interval can be increased while decreasing the peak laser intensity to remain below the damage threshold of the optical fiber.
It should be noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content and/or context clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content or context clearly dictates otherwise.
It should also be noted that, as used in this specification and the appended claims, the phrase “configured” describes a system, apparatus, or other structure that is constructed or configured to perform a particular task or adopt a particular configuration. The phrase “configured” can be used interchangeably with other similar phrases such as arranged and configured, constructed and arranged, constructed, manufactured and arranged, and the like.
As used herein, the recitation of numerical ranges by endpoints shall include all numbers subsumed within that range, inclusive (e.g., 2 to 8 includes 2, 2.1, 2.8, 5.3, 7, 8, etc.).
It is recognized that the figures shown and described are not necessarily drawn to scale, and that they are provided for ease of reference and understanding, and for relative positioning of the structures.
The headings used herein are provided for consistency with suggestions under 37 CFR 1.77 or otherwise to provide organizational cues. These headings shall not be viewed to limit or characterize the invention(s) set out in any claims that may issue from this disclosure. As an example, a description of a technology in the “Background” is not an admission that technology is prior art to any invention(s) in this disclosure. Neither is the “Summary” or “Abstract” to be considered as a characterization of the invention(s) set forth in issued claims.
The embodiments described herein are not intended to be exhaustive or to limit the invention to the precise forms disclosed in the following detailed description. Rather, the embodiments are chosen and described so that others skilled in the art can appreciate and understand the principles and practices. As such, aspects have been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope herein.
It is understood that although a number of different embodiments of the catheter systems have been illustrated and described herein, one or more features of any one embodiment can be combined with one or more features of one or more of the other embodiments, provided that such combination satisfies the intent of the present invention.
While a number of exemplary aspects and embodiments of the catheter systems have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such modifications, permutations, additions and sub-combinations as are within their true spirit and scope, and no limitations are intended to the details of construction or design herein shown.
This application claims priority on U.S. Provisional Application Ser. No. 63/067,780, filed on Aug. 19, 2020, and entitled, “FASTER RISE TIME PULSE SHAPING OF PLASMA GENERATED PRESSURE WAVES FOR DISRUPTION OF VASCULAR CALCIUM”. As far as permitted, the contents of U.S. Provisional Application Ser. No. 63/067,780 are incorporated in their entirety herein by reference.
Number | Date | Country | |
---|---|---|---|
63067780 | Aug 2020 | US |